Parkinson's disease: A Review from the Pathophysiology to Diagnosis, New Perspectives for Pharmacological Treatment.
Parkinson's disease (PD) is the second most common neurodegenerative disease in the elderly, with a higher prevalence in men, independently of race and social class; it affects approximately 1.5 to 2.0% of the elderly population over 60 years old and 4% of people over 80 years old. PD is caused by the necrosis of dopaminergic neurons in the substantia nigra, which is the brain region responsible for the synthesis of the neurotransmitter dopamine (DA), resulting in a decrease of DA in the synaptic cleft. The monoamine oxidase B (MAO-B) degrades the dopamine, promoting the glutamate accumulation and oxidative stress with the release of free radicals, causing the excitotoxicity. The PD symptoms are the progressive physical limitation such as rigidity, bradykinesia, tremor, postural instability, and disability in the functional performance. Considering that there are no laboratory tests, biomarkers or imaging studies to confirm the disease, the diagnosis of PD is made by analyzing the motor features. There is no cure for PD, and the pharmacological treatment acts as a dopaminergic supplement with levodopa, COMT inhibitors, anticholinergics agents, dopaminergic agonists, and inhibitors of MAO-B, which basically aim to control the symptoms, but enabling a better functional mobility, increasing the life expectancy of treated PD patients. Due to the importance and increasing prevalence of PD in the world, this study reviews information of the pathophysiology, symptomatology, and the most current and relevant treatments of PD patients.